CL2022001376A1 - Proteínas gpcr de opsinas quiméricas - Google Patents

Proteínas gpcr de opsinas quiméricas

Info

Publication number
CL2022001376A1
CL2022001376A1 CL2022001376A CL2022001376A CL2022001376A1 CL 2022001376 A1 CL2022001376 A1 CL 2022001376A1 CL 2022001376 A CL2022001376 A CL 2022001376A CL 2022001376 A CL2022001376 A CL 2022001376A CL 2022001376 A1 CL2022001376 A1 CL 2022001376A1
Authority
CL
Chile
Prior art keywords
gpcr
opsin
chimeric
protein
chimeric opsin
Prior art date
Application number
CL2022001376A
Other languages
English (en)
Inventor
Kleinlogel Sonja
Van Wyk Michiel
Original Assignee
Univ Bern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Bern filed Critical Univ Bern
Publication of CL2022001376A1 publication Critical patent/CL2022001376A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5403—IL-3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/007—Vector systems having a special element relevant for transcription cell cycle specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporciona una proteína GPCR de opsina quimérica que comprende una porción de opsina cadena arriba fotosensible y una porción de GPCR diana que comprende un CT quimérico que se expresa fuertemente y se dirige al compartimento subcelular correcto de las células diana. La proteína GPCR de opsina quimérica activa de forma eficaz la proteína G nativa específica de la vía de GPCR diana induciendo una respuesta fisiológica comparable a la del GPCR diana nativo. También se proporcionan moléculas de ácido nucleico que codifican la proteína GPCR de opsina quimérica así como cápsides, vectores, células y vehículos que comprenden o expresan la proteína GPCR de opsina quimérica. Asimismo, se proporciona un método de manipulación por ingeniería genética de una proteína GPCR de opsina quimérica y aplicaciones médicas de la proteína GPCR de opsina quimérica.
CL2022001376A 2019-11-29 2022-05-25 Proteínas gpcr de opsinas quiméricas CL2022001376A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH15092019 2019-11-29

Publications (1)

Publication Number Publication Date
CL2022001376A1 true CL2022001376A1 (es) 2023-03-24

Family

ID=73726778

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022001376A CL2022001376A1 (es) 2019-11-29 2022-05-25 Proteínas gpcr de opsinas quiméricas

Country Status (17)

Country Link
US (1) US20240174743A1 (es)
EP (1) EP4065153A1 (es)
JP (1) JP2023504136A (es)
KR (1) KR20220111294A (es)
CN (1) CN115038458A (es)
AU (2) AU2020392702B2 (es)
BR (1) BR112022010095A2 (es)
CA (1) CA3162568A1 (es)
CL (1) CL2022001376A1 (es)
CO (1) CO2022008784A2 (es)
CR (1) CR20220283A (es)
EC (1) ECSP22050231A (es)
IL (1) IL293076A (es)
JO (1) JOP20220128A1 (es)
MX (1) MX2022006496A (es)
PE (1) PE20230093A1 (es)
WO (1) WO2021105509A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL313755A (en) * 2021-12-20 2024-08-01 Genans Biotechnology Co Ltd An ultralight-sensitive neuropsin-based optogenic tool for activating Gq-coupled signaling and/or cell activation
CN118791624A (zh) * 2023-04-11 2024-10-18 苏州星明优健生物技术有限公司 用于治疗视网膜神经退行性疾病的新型gpcr嵌合视蛋白

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3029063T3 (da) * 2011-06-24 2020-01-20 Arctos Medical AG Lysfølsomt chimært GPCR-protein

Also Published As

Publication number Publication date
CA3162568A1 (en) 2021-06-03
MX2022006496A (es) 2022-09-07
AU2020392702A1 (en) 2022-07-21
AU2020392702B2 (en) 2023-07-06
CR20220283A (es) 2022-09-30
JOP20220128A1 (ar) 2023-01-30
AU2020392702A9 (en) 2022-12-08
CN115038458A (zh) 2022-09-09
JP2023504136A (ja) 2023-02-01
KR20220111294A (ko) 2022-08-09
CO2022008784A2 (es) 2022-09-20
AU2023241362A1 (en) 2023-10-26
PE20230093A1 (es) 2023-01-16
WO2021105509A1 (en) 2021-06-03
ECSP22050231A (es) 2022-08-31
EP4065153A1 (en) 2022-10-05
IL293076A (en) 2022-07-01
BR112022010095A2 (pt) 2022-09-06
US20240174743A1 (en) 2024-05-30

Similar Documents

Publication Publication Date Title
CL2022001376A1 (es) Proteínas gpcr de opsinas quiméricas
BR112016017736A2 (pt) métodos e produtos para produção e distribuição de ácido nucleico
MX2018011384A (es) Arn de replicacion en trans.
CY1122800T1 (el) Συνθεσεις του παραγοντα viii και μεθοδοι δημιουργιας και χρησης αυτων
PE20190401A1 (es) Novedosas proteinas de la capside del virus adenoasociado
EA202092093A1 (ru) Композиции и способы перепрограммирования tcr с применением слитых белков
MX2018001040A (es) Moleculas de acido nucleico artificiales.
MX2022015081A (es) Variantes de hsd17b13 y usos de las mismas.
CL2019003842A1 (es) Vectores virales recombinantes con tropismo modificado y usos de estos para la introducción dirigida de material genético a células humanas.
EA201492202A1 (ru) Способ экспрессии гетерологичных белков с использованием рекомбинантного вирусного вектора с минус-нитью рнк
BR112017009177A2 (pt) vacinas terapêuticas contra hpv16
BR112012015005A2 (pt) Proteínas cry inseticidas cry1ca modificadas
AR092152A1 (es) Uso de una region no traducida de maiz para expresion transgenica en plantas
NZ752941A (en) Frataxin expression constructs
AR100310A1 (es) Moléculas para transporte de antígeno modular mejoradas y sus usos
BR112022008663A2 (pt) Ácidos nucleicos, vetores, células hospedeiras e métodos para a produção de beta-frutofuranosidase de aspergillus niger
UY39245A (es) Ácido nucleico codón-optimizado que codifica la proteína smn1 y su uso
CO2022004535A2 (es) Secuencia de extensión n-terminal para la expresión de péptidos terapéuticos recombinantes
PH12019502442A1 (en) Variants of human bmp7 protein
CO2022013638A2 (es) Enzimas para la sialilación de glicanos
EA201690634A1 (ru) Новая гетеро-трансгликозилаза и ее применение
EA202091536A1 (ru) Конструкция нуклеиновой кислоты для экспрессии генов in vitro и in vivo
AR120358A1 (es) Proteínas cdkl5 recombinantes, terapia génica y métodos de producción
CL2024000680A1 (es) Promotor inducible, vector y célula huésped basados en él
ECSP24013031A (es) Metodo para obtener una cápside de virus adeno-asociada modificada